Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $93

Benzinga · 2d ago
Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $92 to $93.